688 related articles for article (PubMed ID: 18652557)
1. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Torres-Madriz G; Boucher HW
Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
[TBL] [Abstract][Full Text] [Related]
2. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
4. [Gastrointestinal cytomegalovirus infections in organ transplant patients].
Péter A; Telkes G; Varga M; Járay J
Orv Hetil; 2008 Dec; 149(52):2463-70. PubMed ID: 19087914
[TBL] [Abstract][Full Text] [Related]
5. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
Asberg A; Rollag H; Hartmann A
Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
[TBL] [Abstract][Full Text] [Related]
6. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
Bruminhent J; Rotjanapan P; Watcharananan SP
Transplant Proc; 2017 Jun; 49(5):1048-1052. PubMed ID: 28583524
[TBL] [Abstract][Full Text] [Related]
8. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
Martin M; Goyette N; Ives J; Boivin G
J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
[TBL] [Abstract][Full Text] [Related]
9. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients.
Razonable RR
Infect Dis Clin North Am; 2013 Jun; 27(2):317-42. PubMed ID: 23714343
[TBL] [Abstract][Full Text] [Related]
10. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
Singh N
Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
[TBL] [Abstract][Full Text] [Related]
11. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
Kalil AC; Freifeld AG; Lyden ER; Stoner JA
PLoS One; 2009; 4(5):e5512. PubMed ID: 19436751
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
Boivin G; Goyette N; Gilbert C; Humar A; Covington E
Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
[TBL] [Abstract][Full Text] [Related]
13. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis against herpesvirus infections in transplant recipients.
Ljungman P
Drugs; 2001; 61(2):187-96. PubMed ID: 11270937
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
[TBL] [Abstract][Full Text] [Related]
16. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.
Bueno J; Ramil C; Green M
Paediatr Drugs; 2002; 4(5):279-90. PubMed ID: 11994033
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus in Solid Organ Transplant Recipients: Clinical Updates, Challenges and Future Directions.
Razonable RR
Curr Pharm Des; 2020; 26(28):3497-3506. PubMed ID: 32473617
[TBL] [Abstract][Full Text] [Related]
18. Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients.
Falagas ME; Vardakas KZ
Clin Microbiol Infect; 2006 Jul; 12(7):603-5. PubMed ID: 16774555
[TBL] [Abstract][Full Text] [Related]
19. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy.
Singh N
Rev Med Virol; 2006; 16(5):281-7. PubMed ID: 16878336
[TBL] [Abstract][Full Text] [Related]
20. Treatment of congenital cytomegalovirus: where are we now?
Michaels MG
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):441-8. PubMed ID: 17547508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
